跳至主要内容
临床试验/ISRCTN12578022
ISRCTN12578022已完成Unknown

A randomized, double-blind, controlled trial to evaluate the effect of esketamine on postoperative depressive symptoms in breast cancer patients undergoing modified radical mastectomy (Esketamine in Breast Cancer-Depression Randomized Trial)

The First Affiliated Hospital of University of South China0 个研究点目标入组 108 人开始时间: 2024年8月25日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
108

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. HAMD-17 score between 8 and 24 (mild to severe depressive symptoms)
  • 2. Age range between 18 and 65 years
  • 3. American Society of Anesthesiologists (ASA) physical status classification of I-II
  • 4. Confirmed diagnosis of breast cancer and planned unilateral radical mastectomy for breast cancer

排除标准

  • 1. HAMD-17 score of greater than 24 or less than 7
  • 2. Other psychiatric disorders (e.g., schizophrenia and bipolar disorder)
  • 3. History of psychiatric disorders prior to the study
  • 4. Patients who have used psychotropic medications or have other serious systemic illnesses (including serious heart, kidney, or liver disease)
  • 5. Contraindication or allergy to the use of esketamine
  • 6. Planned surgery other than radical mastectomy alone (e.g., reconstruction)

研究者

发起方
The First Affiliated Hospital of University of South China

相似试验